Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial – Labiotech.eu (blog)
Labiotech.eu (blog) |
Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial
Labiotech.eu (blog) Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a … |
